Baricitinib Performs Well in Adolescents With Severe AA. Is a Label Update in the Cards?
Baricitinib (Olumiant, Eli Lilly and Company) produces significant hair regrowth in adolescents with severe alopecia areata (AA), according to results from a 52-week Phase 3 randomized trial presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, NV.